Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
- Conditions
- Co-morbidityRelapseMultiple MyelomaRefractoryAging
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05911321
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: Pro-miniCHOP-like regimenDrug: R-miniCHOP-like regimen
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 35
- Registration Number
- NCT05809180
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Multiple MyelomaRelapse Multiple Myeloma
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 83
- Registration Number
- NCT05789303
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- 🇮🇱
The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
🇧🇷Instituto DOr de Pesquisa e Ensino, Sao Paulo, Brazil
🇧🇷AC Camargo Cancer Center, Sao Paulo, Brazil
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇺🇸
Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
🇦🇺Investigational Site Number : 0360001, Saint Leonards, New South Wales, Australia
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Conditions
- Multiple MyelomaGammopathy, MonoclonalParaproteinemiasCorneal DiseaseMultiple Myeloma in RelapseNeoplasms, Plasma CellNeoplasmsBlood Protein DisordersHaematologic Disease
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 48
- Registration Number
- NCT05581875
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT05572515
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇧🇪CHR de la Citadelle, Liege, Belgium
🇧🇷Hospitais Integradaos da Gavea S/A - DF Star, Brasilia, Brazil
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 15
- Registration Number
- NCT05556616
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸Scripps Health, San Diego, California, United States
A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT05556798
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
- Conditions
- Multiple MyelomaMultiple Myeloma, RefractoryMultiple Myeloma in Relapse
- Interventions
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 12
- Registration Number
- NCT05555329
- Locations
- 🇳🇱
VUMedicalCenter, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.